Skip to main content
logo
Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
124.03
+19.09 (18.19%)
Aug 25, 2026, 3:40 PM EDT - Market open

Inhibrx Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-1.30.21.81.327.23
Revenue Growth
-550.00%-88.89%36.88%-81.81%-43.89%
Gross Profit
-103-111.73-177.64-189.84-100.29-64.21
Operating Income
-127.81-135.03-222.29-219.19-115.32-76.56
Net Income
-138.18-140.061,688-241.36-115.33-81.77
Earnings Per Share
-8.88-9.04112.62-20.48-2.88-2.15
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
133.34124.22152.6277.920131.3
Total Debt
181.63107.018.05210.145.0370.47
Net Cash (Debt)
-48.2817.21144.5567.78-5.0360.83
Net Cash Growth
--88.09%113.25%---38.81%
Net Cash Per Share
-3.101.119.655.75-0.131.60

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-131.89-129.79-194.41-193.31-90.81-
Capital Expenditures
-0.01-0.03-2.6-4.59-0.69-
Free Cash Flow
-131.9-129.83-197.01-197.9-91.5-
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
--10386.54%-111143.50%-12176.94%-8769.81%-1058.83%
Pretax Margin
--10773.31%843787.00%-13408.78%-8769.73%-1130.77%
Profit Margin
--10773.46%843786.00%-13408.94%-8769.96%-1130.80%
FCF Margin
--9986.54%-98503.00%-10994.56%-6957.95%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--0.13---
Forward PE
-0.200.20---
PS Ratio
-883.811114.65---